Best of ESMO: pan-tumor highlights
Summary During the European Society for Medical Oncology (ESMO) 2024 scientific meeting, multiple groundbreaking trials from organ-specific studies were reported. Additionally, results from early clinical trials in the tumor-agnostic space, such as the ROME trial and MTA-cooperative PRMT5 inhibition, garnered significant attention and were presented at the Presidential Symposium. The aim of this manuscript is to provide a concise summary of the pan-tumor highlights from ESMO 2024, focusing on developmental therapeutics and novel treatment strategies beyond a specific organ site.
Authors
- Thorsten Fuereder (ORCID: https://orcid.org/0000-0001-5356-6452)
Institutions
- Medical University of Vienna (AT)
Publication Details
- Journal
- memo - Magazine of European Medical Oncology
- Published
- 2025-04-22
- DOI
- https://doi.org/10.1007/s12254-025-01029-4
- Citations
- 2
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 1.87
Funders
- Universität Wien
- Medizinische Universität Wien